Method for treating viral diseases with attenuated virus
AssigneeUnited Cancer Research Institute
InventorsLaszlo K. Csatary, Richard J. Massey
Life of this patent
Estimating the term…
Abstract
A method for treating human disease of viral etiology which employs the administration of a pharmaceutically effective amount of a live attenuated virus. Avian paramyxovirus is the virus preferred for use in live attenuated vaccine form, although other viruses of human and nonhuman origin have also been shown to be effective. The administration of a pharmaceutically effective amount of avian paramyxovirus and avian rotavirus vacciine has been shown to be efficacious in the treatment of Herpes virus infections, hepatitis-A, some cancers, aphthous stomatitis, acquired immune deficiency syndrome (AIDS) and polyarteritis nodosa.
Claims9
A method of significantly increasing the numbers of T-4 helper-inducer T cells, white blood cells and platelets in humans infected with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex and displaying clinical indications of said infection by administering to said infected humans 1000 units of an attenuated avian paramyxovirus by intramuscular injection one time each week for at least four weeks.
A method of treating humans infected with hepatitis B virus or hepatitis C virus and displaying clinical indications of said infection by administering to said infected humans a therapeutically effective amount of an attenuated avian bursa virus vaccine.
A method for reducing the duration of the acute phase of hepatitis infection and significantly enhancing seroconversion in human patients infected with hepatitis B virus, hepatitis C virus or both hepatitis B virus and hepatitis C virus by administering to said infected patients an amount of attenuated avian bursa virus vaccine effective to decrease the length of said acute phase and to enhance seroconversion.
A method of treating human patients infected with hepatitis virus and characterized by positive virus markers for hepatitis virus, abnormal liver function, and abnormal physical and clinical symptoms which causes the production of antibodies to said hepatitis virus and causes said abnormal liver function and said abnormal physical and clinical symptoms to return to normal, said method comprising the administration to an infected patient of an amount of attenuated avian bursa virus vaccine effective to produce said antibodies and to return said liver function and said physical and clinical symptoms to normal.
The method described in claim 16, wherein said virus markers include HAV, HBV and B (non-A non-B)V.
Dependencies are inferred from the claim text.